Population pharmacokinetics of golimumab, an antiĝ€"tumor necrosis factor-α human monoclonal antibody, in patients with psoriatic arthritis

Journal of Clinical Pharmacology

Volumn 49, Issue 9, 2009, Pages 1056-1070

  Xu, Zhenhua ^a   Vu, Thuy ^b   Lee, Howard ^b   Hu, Chuanpu ^a   Ling, Jie ^a   Yan, Hong ^a   Baker, Daniel ^a   Beutler, Anna ^a   Pendley, Charles ^a   Wagner, Carrie ^a   Davis, Hugh M ^a   Zhou, Honghui ^a  

^a CENTOCOR INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Golimumab; Monoclonal antibody; Population pharmacokinetics; Psoriatic arthritis; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; DRUG ANTIBODY; GOLIMUMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG POTENTIATION; FEMALE; FIRST PASS EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARAMETER; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POPULATION RESEARCH; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BODY WEIGHT; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; SMOKING; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTORS; YOUNG ADULT;

EID: 69549107572     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009339192     Document Type: Article

References (28)

1. Boumpas DT, Illei GG, Tassiulas IO Psoriatic arthritis. In: Klippel JH, Crofford LJ, Stone JH, Weyand CM, eds. Primer on the Rheumatic Diseases. Atlanta, Ga ; 2001: 233-238.
2. Gladman DD, Shuckett R., Russell ML, Thorne JC, Schachter RK Psoriatic arthritis (PSA): an analysis of 220 patients. Q J Med. 1987 ; 62: 127-141.
3. Ritchlin C., Haas-Smith SA, Hicks D., Cappuccio J., Osterland CK, Looney RJ Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998 ; 25: 1544-1552.
4. Antoni CE, Kavanaugh A., Kirkham B., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005 ; 52: 1227-1236.
5. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 ; 52: 3279-3289.
6. Zhou H., Jang H., Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007 ; 47: 383-396.
7. Kavanaugh A., McInnes I., Mease P., et al. Golimumab, a new human tumor necrosis factor ?± antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 ; 60: 976-986.
8. Montgomery DC, Peck EA Introduction to Linear Regression Analysis. New York, NY: John Wiley ; 1982: 301-302.
9. Karlsson MO, Savic RM Diagnosing model diagnostics. Clin Pharmacol Ther. 2007 ; 82: 17-20.
10. Ludden TM, Beal SL, Sheiner LB Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm. 1994 ; 22: 431-445.
11. Savic R., Wilkins J., Karlsson MO (Un)informativeness of empirical bayes estimate-based diagnostics. AAPS J. 2006 ; 8: T3360.
12. Maitre PO, Buhrer M., Thomson D., Stanski DR A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm. 1991 ; 19: 377-384.
13. Barrett JS Population pharmacokinetics. In: Schoenwald R, ed. Pharmacokinetics in Drug Discovery and Development. Boca Raton, Fla: CRC Press; 2002: 315-356.
14. Bland JM, Altman DG Multiple significance tests: the Bonferroni method. BMJ. 1995 ; 310: 170.
15. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003 ; 43: 610-623.
16. Parke J., Holford NH, Charles BG A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999 ; 59: 19-29.
17. Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008 ; 35: 185-202.
18. Ng CM, Bruno R., Combs D., Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005 ; 45: 792-801.
19. Sun YN, Lu JF, Joshi A., Compton P., Kwon P., Bruno RA Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol. 2005 ; 45: 468-476.
20. Badolato R., Oppenheim JJ Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum. 1996 ; 26: 526-538.
21. Humira [package insert]. Abbott Park, Ill: Abbott Laboratories ; 2009.
22. Bruno R., Washington CB, Lu JF, Lieberman G., Banken L., Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005 ; 56: 361-369.
23. Radstake TR, Svenson M., Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2008 Nov 19 [Epub ahead of print]; doi:10.1136/ard.2008.092833.
24. Wolbink GJ, Aarden LA, Dijkmans BAC. Dealing with immunogenicity of biologics: assessment and clinical relevance. Curr Opin Rheumatol. 2009 [Epub ahead of print]; doi:10.1097/ BOR.0b013e328329ed8b.
25. Sesardic D., Boobis AR, Edwards RJ, Davies DS A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol. 1988 ; 26: 363-372.
26. Seitz K., Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007 ; 47: 1104-1118.
27. Mascelli MA, Zhou H., Sweet R., et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol. 2007 ; 47: 553-565.
28. Wang W., Wang EQ, Balthasar JP Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008 ; 84: 548-558.